Clinical trials: Cancer, Advanced Solid Tumors
Breast Cancer, Advanced Malignant Solid Tumors
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information…
- Trial name
- NCT00706030
- Testing
- neratinib, vinorelbine
- Where
- 35 sites in United States, Belgium and 9 more
- Volunteers
- 92 people
- Sponsor
- Puma Biotechnology, Inc.
Advanced Solid Tumor
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended…
- Trial name
- NCT04357756
- Testing
- YH001, Toripalimab
- Where
- 3 sites in Australia
- Volunteers
- 29 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Advanced Solid Neoplasms, Lymphoma Neoplasms
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659…
- Trial name
- NCT03338881
- Testing
- [14C]-TAK-659, TAK-659
- Sponsor
- Calithera Biosciences, Inc
Advanced Solid Tumors
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
- Trial name
- NCT07207681
- Testing
- KXV01 TCR Lentinvivo Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Locally Advanced Unresectable or Metastatic Solid Tumors
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors.
- Trial name
- NCT05458219
- Testing
- IBI343, FOLFIRINOX/mFOLFIRINOX, mFOLFOX
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 470 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Cancer
Treatment of Carrying TP53 Harmful Mutations
Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the treatment of advanced refractory solid tumors with TP53 harmful mutations.
- Trial name
- NCT03645200
- Testing
- Fluzoparib combined with Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Second Hospital
Neoplasm Malignant
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Primary Objectives: To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment To determine the pharmacokinetics (PKs) of…
- Trial name
- NCT01140607
- Testing
- Cabazitaxel (XRP6258)
- Where
- 14 sites in United States
- Volunteers
- 56 people
- Sponsor
- Sanofi
Advanced Solid Tumor
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
The goal of this clinical trial is to find a new radioimmunotherapy regimen for advanced malignancies with multiple metastatic after standard treatment failure/drug resistance.
- Trial name
- NCT06173219
- Testing
- Radiotherapy combined with immunotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- China-Japan Friendship Hospital
Solid Tumors
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body
This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful or no treatment exists can take part. This study tests a medicine called BI 907828.
- Trial name
- NCT05613036
- Testing
- [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1), [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2), BI 907828
- Where
- Hungary
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Advanced/Metastatic Solid Tumors
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in…
- Trial name
- NCT04182516
- Testing
- NMS-03305293
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 52 people
- Sponsor
- Nerviano Medical Sciences
Patients with Advanced Solid Tumors
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.
- Trial name
- NCT05970016
- Testing
- TCC1727 tablet（1）, TCC1727 tablet（2）
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Neoplasms
A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors
This open-label, multi-center, dose-escalation study will evaluate the safety, pharmacokinetics, and therapeutic activity of RO6895882 in participants with Carcinoembryonic Antigen (CEA)-positive solid tumors who have progressed…
- Trial name
- NCT02004106
- Testing
- RO6895882
- Where
- 10 sites in United States, Denmark and 6 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.
- Trial name
- NCT04569916
- Testing
- radiotherapy, irinotecan liposome, apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Advanced Solid Tumors
Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer
The main objective of this study is to determine the maximum tolerated dose (MTD) of Oral Paclitaxel. Eligible subjects of this study are patients with histologically or cytologically confirmed malignant solid tumor refractory to…
- Trial name
- NCT01491204
- Testing
- Paclitaxel+HM30181
- Volunteers
- 25 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of ADRX-0706 in Select Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
- Conditions
- Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
- Trial name
- NCT06036121
- Testing
- ADRX-0706
- Where
- 21 sites in United States, China
- Volunteers
- 144 people
- Sponsor
- Adcentrx Therapeutics
Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
The primary objectives of this study are to evaluate the safety and tolerability of AMG 794 in adult participants and to determine the optimal biological active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1…
- Conditions
- Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
- Trial name
- NCT05317078
- Testing
- AMG 794
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- Amgen
Solid Tumor Malignancies
Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors
This is a Phase 1 clinical study investigating RH125 as monotherapy or in combination therapy in patients with locally advanced or metastatic solid tumors who failed standard treatment, or were intolerant to standard treatment…
- Trial name
- NCT07182435
- Testing
- personalized neoantigen mRNA tumor vaccine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
This study is being done to investigate the safety, tolerability and anti-tumor activity of pembrolizumab (MK-3475) in participants with advanced triple negative breast cancer (TNBC) (Cohort A), advanced head and neck cancer…
- Trial name
- NCT01848834
- Testing
- Pembrolizumab
- Volunteers
- 297 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib.
- Trial name
- NCT05949632
- Testing
- INCB099280, axitinib
- Where
- 6 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.